GlassScriptPhysician profile
John A Wilson
NPI 1679943914
$1,755.85
in general payments reported to CMS, 2019-2025
19 companies · $632 in 2025
The $632 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $84.34 · 2023: $503 · 2024: $536 · 2025: $632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,672.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,671.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $288.12 | 2023-2024 | |
| Lilly USA, LLC | $245.66 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $238.66 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $204.13 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Exact Sciences Corporation | $146.39 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Corcept Therapeutics | $144.75 | 2025 | Korlym |
| Lundbeck LLC | $105.90 | 2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $80.17 | 2024-2025 | Airsupra, Breztri |
| Mylan Specialty L.P. | $53.25 | 2023-2024 | Yupelri |
| Irhythm Technologies, INC. | $43.95 | 2022-2024 | Zio Monitor, Zio Xt Patch |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.98 | 2025 | Jardiance |
| Mayne Pharma Commercial LLC | $28.55 | 2023 | |
| Amgen INC. | $28.12 | 2025 | Krystexxa, Otezla, Repatha |
| Antares Pharma, INC. | $23.42 | 2024 | Xyosted |
| Optinose US, INC. | $22.68 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $20.90 | 2025 | Zoryve |
| Dynavax Technologies Corporation | $18.06 | 2025 | Heplisav-B |
| Phathom Pharmaceuticals, INC. | $16.77 | 2025 | Voquezna |
| Tolmar, INC. | $16.39 | 2025 | Jatenzo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.